[go: up one dir, main page]

AR056369A1 - Compuestos derivados de quinazolina y composicion farmaceutica - Google Patents

Compuestos derivados de quinazolina y composicion farmaceutica

Info

Publication number
AR056369A1
AR056369A1 ARP060102205A ARP060102205A AR056369A1 AR 056369 A1 AR056369 A1 AR 056369A1 AR P060102205 A ARP060102205 A AR P060102205A AR P060102205 A ARP060102205 A AR P060102205A AR 056369 A1 AR056369 A1 AR 056369A1
Authority
AR
Argentina
Prior art keywords
quinazoline
pharmaceutical composition
compounds derived
formula
preparation
Prior art date
Application number
ARP060102205A
Other languages
English (en)
Inventor
Kevin Michael Foote
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0510963A external-priority patent/GB0510963D0/en
Priority claimed from GB0600743A external-priority patent/GB0600743D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR056369A1 publication Critical patent/AR056369A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de formula (1) util en el tratamiento de enfermedades, en particular enfermedades proliferativas como por ejemplo cáncer y para utilizar en la preparacion de medicamentos para su uso en el tratamiento de enfermedades proliferativas; procesos para la preparacion de dichos compuestos, así como composiciones farmacéuticas que los contienen como ingrediente activo. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1), o una sal o prodroga del mismo, donde R1 es hidrogeno o metilo y X es un enlace u oxígeno.
ARP060102205A 2005-05-28 2006-05-26 Compuestos derivados de quinazolina y composicion farmaceutica AR056369A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0510963A GB0510963D0 (en) 2005-05-28 2005-05-28 Chemical compounds
GB0600743A GB0600743D0 (en) 2006-01-14 2006-01-14 Chemical compounds

Publications (1)

Publication Number Publication Date
AR056369A1 true AR056369A1 (es) 2007-10-10

Family

ID=36753382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102205A AR056369A1 (es) 2005-05-28 2006-05-26 Compuestos derivados de quinazolina y composicion farmaceutica

Country Status (7)

Country Link
US (1) US20080194556A1 (es)
EP (1) EP1888572A1 (es)
JP (1) JP2008542345A (es)
AR (1) AR056369A1 (es)
TW (1) TW200716618A (es)
UY (1) UY29561A1 (es)
WO (1) WO2006129064A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82058C2 (uk) * 2001-12-24 2008-03-11 Астразенека Аб Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
WO2010068951A1 (en) * 2008-12-12 2010-06-17 Fox Chase Cancer Center Combination therapy based on src and aurora kinase inhibition for the treatment of cancer
EP2630259B8 (en) * 2010-10-20 2015-05-27 Université de Bordeaux Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors
WO2014103947A1 (ja) 2012-12-25 2014-07-03 日本曹達株式会社 ハロゲン化アニリンおよびその製造方法
CA2929188C (en) 2013-11-20 2022-08-09 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer

Also Published As

Publication number Publication date
US20080194556A1 (en) 2008-08-14
TW200716618A (en) 2007-05-01
WO2006129064A1 (en) 2006-12-07
JP2008542345A (ja) 2008-11-27
EP1888572A1 (en) 2008-02-20
UY29561A1 (es) 2006-12-29

Similar Documents

Publication Publication Date Title
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
SV2008002969A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY30282A1 (es) Compuestos quimicos
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
CR11482A (es) Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa
UY30759A1 (es) Compuestos quimicos
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
PA8591701A1 (es) Derivados de pirrolopirimidina
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2009013501A (es) Compuestos piperidinicos y sus usos.
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY28366A1 (es) Compuestos químicos
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal